Health and Healthcare
OSI Phase III Falls Short (OSIP, DNA)
Published:
Last Updated:
OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is getting hit hard in early trading this morning. The biotech has released data showing that a Phase III trial of Genentech’s (NYSE: DNA) Avastin combined with Tarceva in certain patients with advanced non-small-cell lung cancer did not meet the primary endpoint of increasing overall survival compared with Tarceva plus placebo.
The study assessed cancer patients who had progressed after goingthrough platinum based chemotherapy treatments. One note that thecompany made was that it did show evidence of clinical activity and itsaw improvements in secondary endpoints of progression-free survivaland response rate when Avastin was added to Tarceva compared to Tarcevaalone.
OSI Pharma is getting slammed in the early morning trading on analready tough morning for stocks. Shares are down 13% at $39.77 onabout 6,500 shares. Its 52-week trading range is $32.10 to $53.71.
Jon C. Ogg
October 6, 2008
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
